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CD34+ SELECTED AUTOLOGOUS PERIPHERAL BLOOD STEM CELL 
TRANSPLANTATION FOR MULTIPLE SCLEROSIS (MS): REPORT OF 
TOXICITY AND TREATMENT RESULTS AT ONE YEAR OF FOLLOW-UP 
IN 15 PATIENTS 
Calv'e~'as, E.: Saiz, A.; Ma~'i~, P.; Mm'tiJle~, C.; Rovim, M.; 1,7llmn- 
or, N.; Ayme1"icb, M.; Loza,~o, M.; Fe~wa~dez-Az, iles, F.; Urba';zo- 
Ispizzm, A.; Momse*v'at, E.; Gmus, F. BMT Umt, Hospital Cli*~ic, 
Barcelo~a, Spahz. 
Aim: To report he results of a phase II trial to evaluate feasibili- 
ty and toxicity of CD34+ selected antologous peripheral blood 
stem cell transplantation (CD34+/ASCT) and treatment results at 
one year of follow-up. Design and methods. Patients with 
advanced secondary progressive (SP) or relapsing-remitting (RR) 
MS and confirmed worsening of the extended disability status 
scale (EDSS) in the previous year despite interferon or other 
immunotherapies were included. Peripheral blood stem cells were 
obtained by leukaphereses after mobilization with cyclophos- 
phamide (Cy) and G-CSF. CD34+ selection was performed by 
means of Isolex 300 or CliniMACS devices. BCNU, Cy and ATG 
were administered as conditioning reginmn. Results: Fifteen 
patients (9 SPMS and 6 RRMS) with a median EDSS of 6.0 (4.5- 
6.5) and a median of 3 (1-7) relapses in the previous year were 
included. Mobilization was unsuccessful in one patient. During 
mobilization, one patient presented a transient neurologic deterio- 
ration. Main complications during ASCT were engraftment syn- 
drome en three patients, CMV reactivation i one, and two neu- 
rologic deterioration coinciding with high-fever related to ATG. 
Haematological recovery was fast and complete in all cases. At 12 
months, the EDSS improved in three patients, worsened in two 
and remained stable in nine. Despite withdrawal of all immuno- 
suppressive therapy only two patients presented relapses. MRI 
showed disappearance of enhanced T1 lesions but CSF oligoclon- 
al bands persisted in all evaluated cases. Conclusions: 
CD34+/ASCT using BCNU, Cy and ATG as conditioning regi- 
men has an acceptable toxicity" and clearly" reduces the progression 
of the MS. Further follow-up is necessary to establish the real 
impact of the procedure on the long-reran evolution of the disease. 
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IMMUNOABLATIVE THERAPY WITH PURIFIED AUTOLOGOUS STEM 
CELLS RESCUE FOR THE TREATMENT OF POOR PROGNOSIS MS 
Atkil~s, H.L/; Freedmml, 3/I. z, Bozvma~, 3/i. ; Amel, aV.s: Arllo/d, D/; 
Beme-B~vtckler, L 1;Ba'l"-O~; A. ~, CheJz, J. 3; C,bey~ieJ; R.'; Co'/',rhff, R. s; 
D,quette, P?; Halpemly, M.6; H'aebsch, L. l; Lmzeztvi/lc,, p.7; Lapielv'e, 
2:;; JVlessTlev, H.S; O'Comzov, p.4; Sabloff~ [.1; SekL1]3t ' R.r 1. Otta~Lt 
Hospital-Blood and 3/la'J'vozv Tmmplam Progv'aTH, Ottawa, ON, Cmm- 
cla; 2. Ottawa Hospiml-3/IS CliTtic, Ottawa, ON, Cmmda; 3. z]Iom';'eal 
Neztrologie l';,stitme, Morainal, ON, Cmmda; 4. St MichaelS" Hospital, 
Toromo, ON, Carmda; 5. Umvevsitv of Mom;'eal, Montreak ON, 
-GamMa; 6. Stem Cell Lab - Cmmdh71z Blood SeJz&'es', Otta'a~a, ON, 
Cm~ada; 7. McGill UMve~'sity, Momveak ON, C:,mada, 8. UMversity 
Health Network, To';'onto, ON, Cmmda. 
Chronic immune modulation is partially effective in slowing the 
progression of multiple sclerosis (MS). Intensive conditioning reg- 
imens ablate host inmmnity mediating allograft rejection and thus 
should be capable of ablating dysfunctional autoreactive immuni- 
ty. Stringent depletion of inmmne cells in the graft eliminate GvH 
reactions and hematopoietic stem cells (HSC) reconstitute a naive 
graft-derived immune system. As autoimmunity is an acquired 
defect of the imnmne system, purified stem cells t¥om patients 
with autoimmune diseases hould reconstitute an inmmne system 
free of autoreactivity. We are testing these hypotheses in a phase 
II study of 24 MS patients. Patients are chosen on the basis of 
rapid aggressive arly disease and failure to respond to approved 
disease-modifying drugs. Following baseline evaluations and a 
back-up bone marrow harvest, HSC are mobilized using G-CSF, 
Decadron and Cyclophosphamide and collected by leukopheresis. 
Autologous HSC are purified on a CliniMACS. Reinfusion of 
highly purified HSC follows treatment with Busulphan (~I6 
mg/kg dose adjusted to AUC of the first dose), Cyclophosphamide 
(200 mg/kg), and rabbit anti-thymocyte globulin (5 mg/kg). Five 
patients have been treated. Peripheral blood stem ceils (PBSC) 
were mobilized and collected with nominal toxicity. Immune cell 
contamination f the purified HSCs were below the level of detec- 
tion by FACS. The mobilization regimen did not cause worsening 
of MS by clinical or MRI exam. The expected regimen related 
toxicities were minimal following peripheral blood stem cell trans- 
plant. The MS has remained stable in all patients (3-12 months 
post transplan 0. Signs of central nervous ystem inflammation on 
MRI have resolved following treatment. All patients remain pro- 
foundly deficient in T lymphocytes. Although only early follow- 
up is available, complete immune ablation with stem cell rescue 
for MS appears to be well tolerated and no sign of active disease 
can be detected providing preliminary support for role of 
immunoablative therapy in autoimmunity. 
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RE-INFUSED AUTOLOGOUS GRAFT NATURAL KILLER CELLS CORRE- 
LATES WITH ABSOLUTE LYMPHOCYTE COUNT RECOVERY AFTER 
AUTOLOGOUS STEM CELL TRANSPLANTATION: A PILOT STUDY 
Pox'rata, L.F.; Gdstmeal~, D.A.; Pad/ey, D.; BmMy, K.; 3/im-kovic, S.N. 
Mlt~po clime, Roc,%stel; MN. 
Early absolute lymphocyte count (ALC) has been reported to be 
a powerful prognostic indicator of survival after autologous tern 
ceil transplantation (ASCT). One possible source affecting ALC 
recovery includes the re infused autologous graft lymphocytes 
(AGL). To assess if the re-infused AGL correlate with ALC 
recovery post-ASCT, we conducted a pilot study to identify which 
of the re-infused AGL subsets i  most associated with day 15 ALC 
recovery in three patients with multiple myeloma and four 
patients with non-Hodgkin's lymphoma. Using the Spearman 
rank correlation coefficient analysis (r), we compared absolute 
nmnbers of CD3, CD4, CD8, CD19, and CD16+/CD56+/CD3- 
cells/kg of body weight from the apheresis product with ALC 
(cells/ul) at day 15 post-ASCT. The main lymphocyte subsets 
identified in the apheresis product were T cells and NK cells. 
There was no strong correlation between T or B ceils from the 
apheresis product compared with ALC at day 15 post-ASCT 
(CD3, r=0.21; CD4, r=0.32; CD8, r=0.39; and CD19, r-0.14). 
However, there was good correlation between NK cells from the 
apheresis product compared with ALC at day i5 post-ASCT 
(CD16+/CD56+/CD3-, r=0.77). These data provide preliminary 
evidence that the number of re-infused autologous NK cells in the 
apheresis product significantly affect ALC recovery early post- 
ASCT. However, given the small sample size, our results are pri- 
marily hypothesis-generating and subject of further research. 
151 
PAR~,METERS FOR OPTIMAL TIMING FOR HEMATOPOIETIC PROGEN- 
ITOR CELL COLLECTION 
Kol<, B.; ~7obI~, ~':S.; Loscalzo, J.; Malavade, V.; Bl~ct3l, imh'r, ,4.; 
Baye~; R. Hematology/Omolog 3, North Shorn Umvevsi U Hospital, 
M)Td3nsset, N~'~ 
Controversies exist regarding the timing of leukapheresis for 
peripheral blood progenitor cell (PBPC) collection. Patients are 
often subjected to multiple procedures to collect sufficient nmnber 
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